Oncotalks | Powered by Novartis

ESMO 2019 Highlights on melanoma presented at ESMO 2019

ESMO , Latvia , Lithuania , Estonia , Hungary , Albania
Share this item

Philippe Saiag, MD, PhD and Prof. Jean Jacques Grob, MD are sharing their personal hightlights on melanoma from ESMO 2019

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania

00:03:29

ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)

ASCO , Latvia , Lithuania , Estonia , Hungary , Albania

00:10:57

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

Conleth Murphy, MD, PhD and Ivan Bilic, MD, PhD sharing their personal highlights on breast cancer presented at ESMO 2019 in Barcelona

ESMO , Latvia , Lithuania , Estonia , Albania

00:02:21

EHA 2019 Srdan Verstovsek, MD, PhD - educational session MPN

EHA 2019 Srdan Verstovsek, MD, PhD - educational session MPN

Srdan Verstovsek, MD, PhD from the MD Anderson Center, Houston, USA is commenting on the educational session on MPN, which took place during EHA 2019 in Amsterdam

EHA , Countries , Latvia , Lithuania , Estonia , Albania

00:05:41

ASCO 2019 Dr. Susan Dent

ASCO 2019 Dr. Susan Dent

Dr. Susan Dent from the Duke Cancer Institute, North Carolina, VS is commenting on Reference: DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)

ASCO , Latvia , Lithuania , Estonia , Albania , Slovenia

00:05:01

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Hungary , Lithuania , Albania

00:03:01